News
FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.
Insmed’s Brinsupri scores landmark FDA nod in bronchiectasis, marking first approval of a DPP1 inhibitor
With a landmark U.S. approval Tuesday, Insmed is making waves with a new class of drug that’s also the first to be green lit in the chronic lung disease bronchiectasis. | The FDA on Tuesday signed off on Insmed’s brensocatib to treat non-cystic fibrosis bronchiectasis (NCFBE) in adults and kids ages 12 and up.
Stocktwits on MSN3d
HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week
H.C. Wainwright on Wednesday doubled its price target on Insmed (INSM) to $240 from $120 while keeping a ‘Buy’ rating on the ...
Maxor Specialty Pharmacy, a VytlOne company, was selected by Insmed to be a limited distribution provider of Brinsupri™. Brinsupri is a dipeptidyl peptidase 1 (DPP1) inhibitor indicated for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback